Keyphrases
A1 Receptor
100%
Receptor Agonist
100%
Glucagon-like
100%
Liraglutide
100%
Therapeutic Benefits
100%
GLP-1 Receptor Agonist
100%
Nonglycemic Effect
100%
Hypertension
25%
Systolic Blood Pressure
25%
Beneficial Effects
25%
Type 2 Diabetic Patients
25%
Glycemic Control
25%
Central Nervous System
25%
Obesity
25%
Clinical Trials
25%
Nausea
25%
Diarrhea
25%
Exenatide
25%
Agonist Treatment
25%
Cell Function
25%
Pancreas
25%
Protective Behavior
25%
Insulin Release
25%
Long-term Clinical Study
25%
Cell Dysfunction
25%
Clinical Trial Data
25%
Gastrointestinal Side Effects
25%
Glucagon-like peptide-1 (GLP-1)
25%
Exenatide Once Weekly
25%
Pancreatic Cells
25%
Safety Aspects
25%
Glucagon-like peptide-1 Receptor (GLP-1R)
25%
Gastrointestinal Tolerability
25%
Pre-clinical and Clinical Trials
25%
Pharmacology, Toxicology and Pharmaceutical Science
Liraglutide
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Clinical Trial
40%
Exendin 4
40%
Adverse Event
20%
Non Insulin Dependent Diabetes Mellitus
20%
Tolerability
20%
Nausea
20%
Clinical Study
20%
Glucagon-Like Peptide-1
20%
Diarrhea
20%
Glucagon-Like Peptide 1 Receptor
20%